These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 30511349)

  • 1. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
    Batista AF; Bodart-Santos V; De Felice FG; Ferreira ST
    CNS Drugs; 2019 Mar; 33(3):209-223. PubMed ID: 30511349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C
    Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J; Blunt E; Gupta D; Edison P
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
    Calsolaro V; Edison P
    CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C
    Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C
    Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS; Choi HI; Wang Y; Luo Y; Hoffer BJ; Greig NH
    Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
    Hölscher C
    Biochem Soc Trans; 2014 Apr; 42(2):593-9. PubMed ID: 24646283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
    Athauda D; Foltynie T
    Drug Discov Today; 2016 May; 21(5):802-18. PubMed ID: 26851597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
    Hölscher C
    Neuropharmacology; 2024 Aug; 253():109952. PubMed ID: 38677445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
    Hölscher C
    Br J Pharmacol; 2022 Feb; 179(4):695-714. PubMed ID: 33900631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of spinal GLP-1 receptor signaling.
    Zhang D; Lv G
    Peptides; 2018 Mar; 101():89-94. PubMed ID: 29329976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.
    Duarte AI; Candeias E; Correia SC; Santos RX; Carvalho C; Cardoso S; Plácido A; Santos MS; Oliveira CR; Moreira PI
    Biochim Biophys Acta; 2013 Apr; 1832(4):527-41. PubMed ID: 23314196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight.
    Monti G; Gomes Moreira D; Richner M; Mutsaers HAM; Ferreira N; Jan A
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C
    Recent Pat CNS Drug Discov; 2010 Jun; 5(2):109-17. PubMed ID: 20337586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
    Athauda D; Foltynie T
    Neuropharmacology; 2018 Jul; 136(Pt B):260-270. PubMed ID: 28927992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM; Egefjord L; Gejl M; Steffensen C; Stecher CW; Smidt K; Brock B; Rungby J
    Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.
    Hölscher C
    CNS Drugs; 2012 Oct; 26(10):871-82. PubMed ID: 22938097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.